Comparison of the Protective Effect Amongst Anticholinergic Drugs on Methacholine-Induced Bronchoconstriction in Asthma

References

• Gross N J. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006; 533: 36–39
   PubMed Web of Science ®Google Scholar
• Barnes P J. Neural control of human airways in health and disease. Am Rev Respir Dis 1986; 134: 1289–1314
   PubMed Web of Science ®Google Scholar
• Chapman K R. The role of anticholinergic bronchodilators in adult asthma and COPD. Lung 1990; 168: 295–303
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2005, www.goldcopd.com NHLBI/WHO workshop report
   Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD 1997, NIH Publication 974051
   Google Scholar
• Rodrigo G J, Rodrigo C. The role of Anticholinergics in acute asthma treatment. Chest 2002; 121: 1977–1987
   PubMed Web of Science ®Google Scholar
• Quezada A, Mallol J, Moreno J, Rodriguez J. Effect of different inhaled bronchodilators on recovery from methacholine-induced bronchoconstriction in asthmatic children. Pediatr Pulmonol 1999; 28: 125–129
   PubMed Web of Science ®Google Scholar
• Gross N J, Skorodin M S. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984; 129: 856–870
   PubMed Web of Science ®Google Scholar
• Magnussen H, Nowak D, Wiebicke W. Effect of inhaled ipratropium bromide on the airway response to methacholine, histamine and exercise in patients with mild bronchial asthma. Respiration 1992; 59: 42–47
   PubMed Web of Science ®Google Scholar
• Crimi N, Palermo F, Olivieri R, Polosa R, Settinieri I, Mistretta A. Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma. Eur Respir J 1992; 5: 560–565
   PubMed Web of Science ®Google Scholar
• Sposato B, Mariotta S, Ricci A, Bruno P, Terzano C, Mannino F. The influence of Ipratropium Bromide in the recovery phase of methacholine induced-bronchospasm. Eur Rev Med Pharmacol Sci 2005; 9117–123
   Google Scholar
• Wilson N M, Green S, Coe C, Barnes P J. Duration of protection by oxitropium bromide against cholinergic challenge. Eur J Respir Dis 1987; 71: 455–458
   PubMedGoogle Scholar
• O'Connor B J, Towse L J, Barnes P J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154: 876–880
   PubMed Web of Science ®Google Scholar
• Terzano C, Petroianni A, Ricci A, D'Antoni L, Allegra L. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci 2004; 8: 259–264
   PubMedGoogle Scholar
• Barnes P J, Belvisi M G, Mak J C, Haddad E B, O'Connor B. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995; 56: 853–859
   PubMed Web of Science ®Google Scholar
• Maesen F PV, Smeets J J, Sledsens T JH, Wald F DM, Cornelissen P JG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1506–1513
   PubMed Web of Science ®Google Scholar
• Frith P A, Jenner B, Dangerfield R, Atkinson J, Drennan C. Oxitropium bromide: dose-response and time-response study on a new anticholinergic bronchodilator drug. Chest 1986; 89: 249–253
   PubMed Web of Science ®Google Scholar
• Pounsford J C, Fuller R W, Saunders K B. A cumulative dose-response study of oxitropium bromide (Ba 253) in asthmatics. Eur J Respir Dis 1983, Suppl 128: 536–539
   Google Scholar
• Sterk P J, Fabbri L M, Quanjer P H, Cockcroft D W, O'Byrne P M, Anderson S D, Juniper E F, Malo J L. Airway responsiveness. Standardized challenge testing with parmacological, physical and sensitizing stimuli in adults. Eur Resp J 1993; 6((suppl)16)53–83
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Guidelines for Methacholine and Exercise Challenge Testing-1999. Am J Respir Crit Care Med 2000; 161: 309–329
   PubMed Web of Science ®Google Scholar
• O'Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose-response curves to methacholine. Am Rev Respir Dis 1987; 136: 1412–1417
   PubMed Web of Science ®Google Scholar
• Reid J K, Davis B E, Cockcroft D W. The effect of Ipratropium nasal spray on bronchial methacholine challenge. Chest 2005; 128: 1245–1247
   PubMed Web of Science ®Google Scholar
• Disse B, Reichal R, Speck G, Travnecker W, Rominger L, Hammer R. Ba679BR, a novel anticholinergic bronchodilator: preclinical and clinical aspects. Life Sci 1993; 52: 537–544
   PubMed Web of Science ®Google Scholar
• Haddad E, Mak J CW, Barnes P J. Characterization of [3H] BA 679. A slow-dissociating muscarinic receptor antagonist in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994; 45: 899–907
   PubMed Web of Science ®Google Scholar
• Peel E T, Anderson G, Cheong B, Broderick N. A comparison of oxitropium bromide and ipratropium bromide in asthma. Eur J Respir Dis 1984; 66: 665–673
   Google Scholar
• Lulling J, Delwiche J P, Prignot J. Early bronchodilating effect of oxitropium bromide in comparison with ipratropium bromide. Respiration 1981; 42: 188–192
   PubMed Web of Science ®Google Scholar
• Gross N J, Petty T L, Friedman M, Skorodin M S, Silvers G W, Donohue J F. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 1989; 139: 1188–1191
   PubMed Web of Science ®Google Scholar